Symbiotic-LungNCT07226999
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer
At risk: Primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 11 versions: 10 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary endpoint(s) modified Show 6 more changesShow less
- Eligibility criteria expanded, about 90 words
- Trial sites expanded: 82 → 85 locations
- Interventions modified
- Trial arms changed: 3 → 5
- Secondary endpoints: 14 to 15
- Study title expanded, about 7 words
- Notable Eligibility criteria expanded, about 11 words
- Primary endpoints: details revised at 1 of 3 entries
- Study sites: 83 to 82
- Secondary endpoints: details revised at 2 of 14 entries
- Minor Trial sites expanded: 73 → 83 locationsv8
- Minor Trial sites expanded: 49 → 73 locationsv7
- Minor Trial sites expanded: 43 → 49 locationsv6
- Minor Trial sites expanded: 32 → 43 locationsv5
- Minor Trial sites expanded: 26 → 32 locationsv4
- Minor Trial sites expanded: 6 → 26 locations
- Secondary endpoints: details revised at 2 of 14 entries
- Study title expanded, about 1 word
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 6
- Start date changed from estimate of Nov 17, 2025 to Dec 9, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (15)
Show 10 moreShow less
Arms and interventions
Participants will receive PF-08634404 in combination with chemotherapy
Participants will receive PF-08634404 in combination with tarlatamab
Participants will receive PF-08634404 in combination with tarlatamab and chemotherapy.
Participants will receive PF-08634404 in combination with chemotherapy
Participants will receive atezolizumab in combination with chemotherapy
Drugs: PF-08634404, Tarlatamab, Chemotherapy, Atezolizumab
Sites
85 sites in 10 countries
United States 55, Spain 7, Japan 4, Puerto Rico 4, Australia 3, Italy 3, Taiwan 3, China 2, France 2, Germany 2